US20190381126A1 - Methods for making conjugates from disulfide-containing proteins - Google Patents
Methods for making conjugates from disulfide-containing proteins Download PDFInfo
- Publication number
- US20190381126A1 US20190381126A1 US16/524,951 US201916524951A US2019381126A1 US 20190381126 A1 US20190381126 A1 US 20190381126A1 US 201916524951 A US201916524951 A US 201916524951A US 2019381126 A1 US2019381126 A1 US 2019381126A1
- Authority
- US
- United States
- Prior art keywords
- polypeptide
- antibody
- protein
- payload
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 59
- 102000004169 proteins and genes Human genes 0.000 title abstract description 87
- 108090000623 proteins and genes Proteins 0.000 title abstract description 87
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 title abstract description 35
- 230000002829 reductive effect Effects 0.000 claims abstract description 26
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 17
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 70
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 67
- 229920001184 polypeptide Polymers 0.000 claims description 65
- 150000001875 compounds Chemical class 0.000 claims description 34
- 125000005647 linker group Chemical group 0.000 claims description 26
- 125000000524 functional group Chemical group 0.000 claims description 10
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 9
- 239000002619 cytotoxin Substances 0.000 claims description 9
- 101710112752 Cytotoxin Proteins 0.000 claims description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- CSVFWMMPUJDVKH-UHFFFAOYSA-N 1,1-dichloropropan-2-one Chemical compound CC(=O)C(Cl)Cl CSVFWMMPUJDVKH-UHFFFAOYSA-N 0.000 claims description 5
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 abstract description 86
- 235000018417 cysteine Nutrition 0.000 abstract description 11
- 150000002576 ketones Chemical class 0.000 abstract description 8
- 229910052799 carbon Inorganic materials 0.000 abstract description 2
- 239000000376 reactant Substances 0.000 abstract description 2
- 230000001268 conjugating effect Effects 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- 239000000562 conjugate Substances 0.000 description 43
- 239000000203 mixture Substances 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 150000003573 thiols Chemical class 0.000 description 20
- 150000002019 disulfides Chemical class 0.000 description 18
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 18
- -1 antibodies Proteins 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 230000021615 conjugation Effects 0.000 description 11
- 0 **(CN1C(=O)C(SC)=C(SC)C1=O)CN1C(=O)C(SC)=C(SC)C1=O.C*N1C(=O)C(Br)=C(Br)C1=O.[H]SC.[H]SC.[H]SC.[H]SC Chemical compound **(CN1C(=O)C(SC)=C(SC)C1=O)CN1C(=O)C(SC)=C(SC)C1=O.C*N1C(=O)C(Br)=C(Br)C1=O.[H]SC.[H]SC.[H]SC.[H]SC 0.000 description 10
- 229940049595 antibody-drug conjugate Drugs 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- SUNMBRGCANLOEG-UHFFFAOYSA-N 1,3-dichloroacetone Chemical compound ClCC(=O)CCl SUNMBRGCANLOEG-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 7
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 7
- 230000022811 deglycosylation Effects 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- MYFOXCMBZIIVSR-UHFFFAOYSA-N 3-[2-[2-[2-(2-aminooxyethoxy)ethoxy]ethoxy]ethoxy]-N-[2-[2-[3-[2-[2-[2-(2-aminooxyethoxy)ethoxy]ethoxy]ethoxy]propanoylamino]ethyl-[3-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]propanoyl]amino]ethyl]propanamide Chemical compound NOCCOCCOCCOCCOCCC(NCCN(C(CCOCCOCCOCCOCCN=[N+]=[N-])=O)CCNC(CCOCCOCCOCCOCCON)=O)=O MYFOXCMBZIIVSR-UHFFFAOYSA-N 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 6
- 239000000611 antibody drug conjugate Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 238000006845 Michael addition reaction Methods 0.000 description 5
- YJIXNJRUGUAIOS-UHFFFAOYSA-N N,N-bis[2-[3-[2-[2-[2-(2-aminooxyethoxy)ethoxy]ethoxy]ethoxy]propanoylamino]ethyl]-6-[3-(phenyldisulfanyl)propanoylamino]hexanamide Chemical compound NOCCOCCOCCOCCOCCC(=O)NCCN(CCNC(CCOCCOCCOCCOCCON)=O)C(CCCCCNC(CCSSC1=CC=CC=C1)=O)=O YJIXNJRUGUAIOS-UHFFFAOYSA-N 0.000 description 5
- STRBHGLRGKUNLX-UHFFFAOYSA-N N-[2-[3-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]propanoyl-[2-[3-[2-[2-[2-[2-(1,3-dioxoisoindol-2-yl)oxyethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]ethyl]amino]ethyl]-3-[2-[2-[2-[2-(1,3-dioxoisoindol-2-yl)oxyethoxy]ethoxy]ethoxy]ethoxy]propanamide Chemical compound N(=[N+]=[N-])CCOCCOCCOCCOCCC(=O)N(CCNC(CCOCCOCCOCCOCCON1C(C2=CC=CC=C2C1=O)=O)=O)CCNC(CCOCCOCCOCCOCCON1C(C2=CC=CC=C2C1=O)=O)=O STRBHGLRGKUNLX-UHFFFAOYSA-N 0.000 description 5
- 125000004450 alkenylene group Chemical group 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 125000002993 cycloalkylene group Chemical group 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- MJJNRJFPCHCDDE-UHFFFAOYSA-N tert-butyl N-[2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyl]amino]ethyl]carbamate Chemical compound N1=C(C=CC=C1)SSCCC(=O)NCCCCCC(=O)N(CCNC(OC(C)(C)C)=O)CCNC(OC(C)(C)C)=O MJJNRJFPCHCDDE-UHFFFAOYSA-N 0.000 description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- ZYMCHMUVFGHEDP-UHFFFAOYSA-N N,N-bis(2-aminoethyl)-6-[3-(phenyldisulfanyl)propanoylamino]hexanamide dihydrochloride Chemical compound Cl.Cl.NCCN(C(CCCCCNC(CCSSC1=CC=CC=C1)=O)=O)CCN ZYMCHMUVFGHEDP-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000002228 disulfide group Chemical group 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- UTFCGQVACYEFTK-UHFFFAOYSA-N tert-butyl N-[2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl-[6-[3-(phenyldisulfanyl)propanoylamino]hexanoyl]amino]ethyl]carbamate Chemical compound C1(=CC=CC=C1)SSCCC(=O)NCCCCCC(=O)N(CCNC(OC(C)(C)C)=O)CCNC(OC(C)(C)C)=O UTFCGQVACYEFTK-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- HLAGLPXQSIDIDX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-(1,3-dioxoisoindol-2-yl)oxyethoxy]ethoxy]ethoxy]ethoxy]propanoate Chemical compound O=C1C2=CC=CC=C2C(=O)N1OCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O HLAGLPXQSIDIDX-UHFFFAOYSA-N 0.000 description 3
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- BIKSKRPHKQWJCW-UHFFFAOYSA-N 3,4-dibromopyrrole-2,5-dione Chemical compound BrC1=C(Br)C(=O)NC1=O BIKSKRPHKQWJCW-UHFFFAOYSA-N 0.000 description 3
- UENRXLSRMCSUSN-UHFFFAOYSA-N 3,5-diaminobenzoic acid Chemical compound NC1=CC(N)=CC(C(O)=O)=C1 UENRXLSRMCSUSN-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000004225 Cathepsin B Human genes 0.000 description 3
- 108090000712 Cathepsin B Proteins 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- GFNZLFKUHWHNAQ-UHFFFAOYSA-N N,N-bis(2-aminoethyl)-3-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]propanamide dihydrochloride Chemical compound Cl.Cl.NCCN(C(CCOCCOCCOCCOCCN=[N+]=[N-])=O)CCN GFNZLFKUHWHNAQ-UHFFFAOYSA-N 0.000 description 3
- HAWKDQFYMFWPET-UHFFFAOYSA-N N,N-bis(2-aminoethyl)-6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanamide dihydrochloride Chemical compound Cl.Cl.NCCN(C(CCCCCNC(CCSSC1=NC=CC=C1)=O)=O)CCN HAWKDQFYMFWPET-UHFFFAOYSA-N 0.000 description 3
- 150000001345 alkine derivatives Chemical class 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000005549 heteroarylene group Chemical group 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- ZABBFAHZPHMIJC-UHFFFAOYSA-N 1,1-Dibromopropan-2-one Chemical compound CC(=O)C(Br)Br ZABBFAHZPHMIJC-UHFFFAOYSA-N 0.000 description 2
- LQQKDSXCDXHLLF-UHFFFAOYSA-N 1,3-dibromopropan-2-one Chemical compound BrCC(=O)CBr LQQKDSXCDXHLLF-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HCFAJYNVAYBARA-UHFFFAOYSA-N CCCC(=O)CCC Chemical compound CCCC(=O)CCC HCFAJYNVAYBARA-UHFFFAOYSA-N 0.000 description 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 2
- FHUFMUWRGOVIHZ-UHFFFAOYSA-N CSCC(=O)CSC.CSCC(=O)CSC.CSCC(=O)CSC.CSCC(=O)CSC.CSCC(=O)CSC.CSCC(=O)CSC Chemical compound CSCC(=O)CSC.CSCC(=O)CSC.CSCC(=O)CSC.CSCC(=O)CSC.CSCC(=O)CSC.CSCC(=O)CSC FHUFMUWRGOVIHZ-UHFFFAOYSA-N 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 229930183665 actinomycin Natural products 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960005501 duocarmycin Drugs 0.000 description 2
- 229930184221 duocarmycin Natural products 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002669 lysines Chemical class 0.000 description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- IDBIFFKSXLYUOT-UHFFFAOYSA-N netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KNORWRWRHNHJAV-UHFFFAOYSA-N tert-butyl n-[2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylamino]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCNCCNC(=O)OC(C)(C)C KNORWRWRHNHJAV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- OIGKWPIMJCPGGD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]propanoate Chemical compound [N-]=[N+]=NCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O OIGKWPIMJCPGGD-UHFFFAOYSA-N 0.000 description 1
- QYEAAMBIUQLHFQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 QYEAAMBIUQLHFQ-UHFFFAOYSA-N 0.000 description 1
- LGNCNVVZCUVPOT-FUVGGWJZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LGNCNVVZCUVPOT-FUVGGWJZSA-N 0.000 description 1
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
- VGLCUHJZKWYDPC-BYPYZUCNSA-N (2s)-2-aminobutane-1,4-dithiol Chemical compound SC[C@@H](N)CCS VGLCUHJZKWYDPC-BYPYZUCNSA-N 0.000 description 1
- BQQGAGGSEMLWRS-UHFFFAOYSA-N (4-aminophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(N)C=C1 BQQGAGGSEMLWRS-UHFFFAOYSA-N 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 description 1
- SGPUHRSBWMQRAN-UHFFFAOYSA-N 2-[bis(1-carboxyethyl)phosphanyl]propanoic acid Chemical compound OC(=O)C(C)P(C(C)C(O)=O)C(C)C(O)=O SGPUHRSBWMQRAN-UHFFFAOYSA-N 0.000 description 1
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 108090001008 Avidin Chemical group 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- DUFWLPNQYVZWCD-POMLCPGFSA-N C.CCC/C(CSC)=N/OCCOCCOCCOCCOCCC(=O)NCCN(CCNC(=O)CCOCCOCCOCCOCCO/N=C(\CCC)CSC)C(=O)CCCCCCC(=O)CCSSC1=CC=CC=C1 Chemical compound C.CCC/C(CSC)=N/OCCOCCOCCOCCOCCC(=O)NCCN(CCNC(=O)CCOCCOCCOCCOCCO/N=C(\CCC)CSC)C(=O)CCCCCCC(=O)CCSSC1=CC=CC=C1 DUFWLPNQYVZWCD-POMLCPGFSA-N 0.000 description 1
- DFCNYGLCZXOUCR-MNEAUPDQSA-N C.CCC/C(CSC)=N/OCCOCCOCCOCCOCCC(=O)NCCN(CCNC(=O)CCOCCOCCOCCOCCO/N=C(\CCC)CSC)C(=O)CCCCCNC(=O)CCSC1CC(=O)N(CCCCCC(=O)N(C)[C@H](C(=O)CC(C(=O)N(C)[C@@H]([C@@H](C)CC)[C@@H](CC(=O)N2CC[C@@H]([C@H](OC)[C@@H](C)C(=O)C[C@@H](CC3=CC=CC=C3)C(=O)O)C2)OC)C(C)C)C(C)C)C1=O Chemical compound C.CCC/C(CSC)=N/OCCOCCOCCOCCOCCC(=O)NCCN(CCNC(=O)CCOCCOCCOCCOCCO/N=C(\CCC)CSC)C(=O)CCCCCNC(=O)CCSC1CC(=O)N(CCCCCC(=O)N(C)[C@H](C(=O)CC(C(=O)N(C)[C@@H]([C@@H](C)CC)[C@@H](CC(=O)N2CC[C@@H]([C@H](OC)[C@@H](C)C(=O)C[C@@H](CC3=CC=CC=C3)C(=O)O)C2)OC)C(C)C)C(C)C)C1=O DFCNYGLCZXOUCR-MNEAUPDQSA-N 0.000 description 1
- MVMGCAANGNUYRU-TXIVYMNSSA-N C.CCC/C(CSC)=N/OCCOCCOCCOCCOCCC(=O)NCCN(CCNC(=O)CCOCCOCCOCCOCCO/N=C(\CCC)CSC)C(=O)CCOCCOCCOCCOCCN=[N+]=[N-] Chemical compound C.CCC/C(CSC)=N/OCCOCCOCCOCCOCCC(=O)NCCN(CCNC(=O)CCOCCOCCOCCOCCO/N=C(\CCC)CSC)C(=O)CCOCCOCCOCCOCCN=[N+]=[N-] MVMGCAANGNUYRU-TXIVYMNSSA-N 0.000 description 1
- XCWHDCABGYSEMB-UHFFFAOYSA-N C.CSCC(CSC)=NOCCOCCOCCOCCOCCC(=O)NCCN(CCNC(=O)CCOCCOCCOCCOCCON=C(CSC)CSC)C(=O)CCOCCOCCOCCOCCN=[N+]=[N-] Chemical compound C.CSCC(CSC)=NOCCOCCOCCOCCOCCC(=O)NCCN(CCNC(=O)CCOCCOCCOCCOCCON=C(CSC)CSC)C(=O)CCOCCOCCOCCOCCN=[N+]=[N-] XCWHDCABGYSEMB-UHFFFAOYSA-N 0.000 description 1
- IYKVLNRFJQSHKC-UHFFFAOYSA-N CCCN(CCNC(=O)OC(C)(C)C)C(=O)CCCCCNC(=O)CCSSC1=CC=CC=C1 Chemical compound CCCN(CCNC(=O)OC(C)(C)C)C(=O)CCCCCNC(=O)CCSSC1=CC=CC=C1 IYKVLNRFJQSHKC-UHFFFAOYSA-N 0.000 description 1
- UBGLQJMONAXZTM-UHFFFAOYSA-N CCCN(CCNC(=O)OC(C)(C)C)C(=O)CCCCCNC(=O)CCSSC1=NC=CC=C1 Chemical compound CCCN(CCNC(=O)OC(C)(C)C)C(=O)CCCCCNC(=O)CCSSC1=NC=CC=C1 UBGLQJMONAXZTM-UHFFFAOYSA-N 0.000 description 1
- ACWPKRSIAVSOOK-UHFFFAOYSA-N CCCN(CCNC(=O)OC(C)(C)C)C(=O)CCOCCOCCOCCOCCN=[N+]=[N-] Chemical compound CCCN(CCNC(=O)OC(C)(C)C)C(=O)CCOCCOCCOCCOCCN=[N+]=[N-] ACWPKRSIAVSOOK-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- JBCOJHKUVYMADK-UHFFFAOYSA-N Cl.Cl.NCCN(CCN)C(=O)CCCCCNC(=O)CCSSC1=CC=CC=C1 Chemical compound Cl.Cl.NCCN(CCN)C(=O)CCCCCNC(=O)CCSSC1=CC=CC=C1 JBCOJHKUVYMADK-UHFFFAOYSA-N 0.000 description 1
- GMHMIRDOVLWBBG-UHFFFAOYSA-N Cl.Cl.NCCN(CCN)C(=O)CCCCCNC(=O)CCSSC1=NC=CC=C1 Chemical compound Cl.Cl.NCCN(CCN)C(=O)CCCCCNC(=O)CCSSC1=NC=CC=C1 GMHMIRDOVLWBBG-UHFFFAOYSA-N 0.000 description 1
- BPAHZRKCSRELJN-UHFFFAOYSA-N Cl.Cl.[N-]=[N+]=NCCOCCOCCOCCOCCC(=O)N(CCN)CCN Chemical compound Cl.Cl.[N-]=[N+]=NCCOCCOCCOCCOCCC(=O)N(CCN)CCN BPAHZRKCSRELJN-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 239000012626 DNA minor groove binder Substances 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 108010052285 Membrane Proteins Chemical group 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010042309 Netropsin Proteins 0.000 description 1
- WLELQBWNKOUWCW-UHFFFAOYSA-N O=C(CCOCCOCCOCCOCCON1C(=O)C2=C(C=CC=C2)C1=O)NCCN(CCNC(=O)CCOCCOCCOCCOCCON1C(=O)C2=C(C=CC=C2)C1=O)C(=O)CCCCCNC(=O)CCSSC1=CC=CC=C1 Chemical compound O=C(CCOCCOCCOCCOCCON1C(=O)C2=C(C=CC=C2)C1=O)NCCN(CCNC(=O)CCOCCOCCOCCOCCON1C(=O)C2=C(C=CC=C2)C1=O)C(=O)CCCCCNC(=O)CCSSC1=CC=CC=C1 WLELQBWNKOUWCW-UHFFFAOYSA-N 0.000 description 1
- VWDDELVBUQQALV-UHFFFAOYSA-N O=C(CCOCCOCCOCCOCCON1C(=O)C2=C(C=CC=C2)C1=O)NCCN(CCNC(=O)CCOCCOCCOCCOCCON1C(=O)C2=C(C=CC=C2)C1=O)C(=O)CCCCCNC(=O)CCSSC1=NC=CC=C1 Chemical compound O=C(CCOCCOCCOCCOCCON1C(=O)C2=C(C=CC=C2)C1=O)NCCN(CCNC(=O)CCOCCOCCOCCOCCON1C(=O)C2=C(C=CC=C2)C1=O)C(=O)CCCCCNC(=O)CCSSC1=NC=CC=C1 VWDDELVBUQQALV-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 239000007819 coupling partner Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine group Chemical group NO AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Chemical group 0.000 description 1
- 239000002157 polynucleotide Chemical group 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000003506 protein modification method Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/04—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Definitions
- payloads have been covalently attached to enzymes, antibodies, and other polypeptides or proteins, to form conjugates.
- the payloads may be used to locate the protein to which they are attached (e.g., labels), to modify the physicochemical properties or stability of the protein (e.g., PEGylation), to enable the protein to be attached to another molecule or protein (functional or coupling groups, for connecting the conjugate to another compound or another conjugate), or to modify the function or activity of the payload or the protein (e.g., vaccine conjugates).
- the protein may also act as a carrier to deliver the attached payload to a particular tissue or cell type, such as in antibody-drug conjugates (ADCs).
- ADCs antibody-drug conjugates
- Classes of payloads that can be usefully linked to proteins include detectable moieties (labels), anchoring moieties to attach the protein to a surface or another compound, antigens that elicit an immune response when conjugated to a protein, coupling groups that react readily with a chemically complementary coupling partner (thus connecting the protein to another entity), and therapeutic moieties such as cytotoxins and other bioactive agents.
- ADCs Attaching these diverse structures to proteins in a controlled and reproducible fashion is often critical for the conjugates to function correctly, particularly when they are used as therapeutic agents.
- ADCs it is important to carefully control the number of payload compounds attached to an antibody, which is not easy since the carrier is a large and complex protein.
- the optimum DAR (drug to antibody ratio) for an ADC may vary from 1 to 6 or more, in order to balance factors such as efficacy, stability, and safety. If ADCs are made as mixtures with varying drug/antibody ratios (DARs), separation is difficult, and consistency of the product is important for both therapeutic and regulatory reasons.
- DARs drug/antibody ratios
- cysteine may be suitable for use as a site for conjugation where it is available in adequate numbers; where too few cysteines are present, one or more may be inserted by standard protein modification methods. However, it is often preferable to avoid modifying the sequence of the natural protein by inserting a cysteine or by removing a disulfide. While it is not difficult to convert a disulfide into two free cysteines by reducing the disulfide, doing so may disrupt the secondary or tertiary structure of the protein.
- Some methods for inserting a tether between cysteine residues formed by reducing a disulfide on a protein have been reported. This approach is particularly appealing for ADC production, because the typical antibody structure contains four reducible inter-chain disulfides that can be utilized without protein engineering.
- One method used for such conjugation involves a sulfone-substituted methacrylate derivative. US2006/0210526. This method forms a reactive intermediate that requires an elimination step before alkylation of the second sulfur atom occurs. The conditions for that multi-step process can result in incomplete formation of a linker (tether) between cysteines, and the reaction conditions can cause protein denaturation.
- Another approach uses a maleimide derivative, e.g., a 3,4-dibromomaleimide. WO2011/018613.
- the tether contains a carbonyl group that is reactive enough to form an oxime linkage with a hydroxylamine group, and the payload is conjugated to the activated protein by forming such linkage.
- the reduced protein can be reacted with a 1,3-dihalo acetone such as dichloroacetone or dibromoacetone, thereby inserting a 3-carbon tether connecting the two sulfur atoms together.
- This may suitably simulate the effect of the disulfide, keeping the protein in a conformation very similar to the one it had when the disulfide was present, while it also provides greater stability than the disulfide as well as a place to attach a payload.
- the tethers used in the methods and compositions of the invention provide a chemically reactive functional group, and a protein containing this type of tether between two cysteine sulfur atoms is referred to herein as an activated protein. While each ketone can be used to attach a payload, in the present invention two such ketones or other tethering groups are connected together with a bridging group that provides a new point of attachment for a payload. As a result of using two S—S tethers to attach a bridging group that carries one payload, the number of payload compounds on a given polypeptide is one-half of the number of disulfides used in the conjugation method.
- the Figures herein provide a schematic representation of the conjugates of the invention.
- FIG. 1 is a scheme illustrating how a disulfide can be activated and used to make a polypeptide-payload conjugate.
- FIG. 2 provides a diagram of a generic antibody, illustrating the presence and position of the inter-chain disulfides that can be used in the methods of the invention for forming conjugates.
- FIG. 4 shows the SDS-PAGE gel of the Fc, 12, and 14 (Example 1).
- FIG. 6 shows the SDS-PAGE gel of the products of Examples 4 and 5.
- Protein and polypeptide as used herein refer to peptides containing ten or more amino acid residues connected by amide (peptide) bonds.
- a protein or polypeptide may be a single continuous strand or it may include two or more strands that associate naturally to form a stable complex, and may be or comprise a cyclic polypeptide.
- the proteins described herein comprise mainly or only naturally occurring amino acids, though the methods described herein are equally useful with polypeptides that contain one or more non-natural amino acids. Commonly (but not necessarily) the amino acids are mostly or entirely of the L configuration and are selected from the common ‘essential’ amino acids.
- the methods are also suitable for use with polypeptide complexes that contain two or more peptide chains, where the disulfide bonds used for the methods of the invention may be inter-chain or intra-chain disulfides.
- EDT Ethane dithiol HBTU N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate MeCN acetonitrile NMP N-methyl pyrrolidinone PBS Phosphate-buffered saline
- FIGS. 3A-3C An example of one embodiment of the invention is shown in FIGS. 3A-3C .
- the Figure depicts a generic antibody schematically, showing four inter-chain disulfide bonds.
- the inter-chain disulfides are all reduced, forming a reduced protein having eight free thiols derived from the disulfides.
- the reduced polypeptide is then allowed to react with a dihaloacetone or similar bis-electrophile (e.g., 1, 3-dichloroacetone or 1,3-dibromoacetone) to form an activated protein wherein each pair of thiols is linked together through a functionalized tether: the tether in this example contains a free ketone group that is reactive toward Schiff base formation.
- a bis-alkoxyamine bridging group is then allowed to react with the ketones of the activated polypeptide, wherein a single payload group is attached to the bridging group.
- the methods of the invention can also be used with other tethering groups between sulfur atoms from a disulfide.
- methods to tie together sulfhydryl groups using cyclic groups are known in the art, using dibromomaleimide with a payload attached to the ring nitrogen.
- These can be adapted to produce conjugates of the invention by tying to of the linker moieties together to form a bridge that carries one payload compound, as depicted here.
- This double-attachment should also reduce potential problems caused by reversible Michael addition of S onto the maleimide ring, which can release the payload (cytotoxin) prematurely.
- the risk of premature release of payload should be reduced.
- a pair of cysteines to be linked together may be on a single polypeptide strand, or they may be on separate polypeptide strands that form a polypeptide complex.
- the methods utilize a protein or polypeptide having 2-6 disulfide linkages, or 4-8 free cysteine residues, and involve reduction of at least two of the disulfides.
- the disulfide-containing polypeptide can be any polypeptide having at least 10 amino acid residues, preferably at least 50 amino acids, that contains a pair of disulfide linkages within a single polypeptide sequence, including a polypeptide complex where a disulfide (or two or more disulfides) connects one polypeptide sequence to another amino acid or polypeptide, provided the complex does not dissociate rapidly when the disulfides are reduced for insertion of the tether between the sulfur atoms.
- Typical proteins for use in the methods of the invention include cyclic peptides and linear peptides containing about 50 to about 5000 amino acids, typically at least 100 amino acids and up to about 2000, including functional proteins such as enzymes or receptors; protein complexes having at least two disulfide linkages (often connecting two separate polypeptide strands); structural proteins; proteins used as vaccine scaffolds such as CRM197 or other proteins having adjuvant activity; and particularly antibodies or antibody fragments having at least two reducible disulfide bonds, e.g., Fc.
- Particularly useful proteins for these methods include antibodies, especially monoclonal antibodies including engineered antibodies, modified antibodies and antibody fragments having two inter-chain disulfides; vaccine carrier proteins such as CRM197; and single-stranded proteins having at least two disulfide linkages or at least four cysteine residues and having a molecular weight between 500 and 500,000, typically between 1,000 and 200,000.
- vaccine carrier proteins such as CRM197
- single-stranded proteins having at least two disulfide linkages or at least four cysteine residues and having a molecular weight between 500 and 500,000, typically between 1,000 and 200,000.
- the methods are especially useful with antibodies and antibody subunits containing at least two reducible disulfides, including IgG and Fc, which have two to four accessible inter-strand disulfide bonds that are readily reduced by methods known in the art.
- the disulfide linkages of disulfide-containing proteins for use in the methods and compositions of the invention are reduced to form four or more free thiol groups: methods for such reduction are well known in the art.
- the reduction is performed using a reducing agent that selectively reduces disulfide linkages that are readily accessible to solvent around the protein: one suitable reducing agent is tris(2-carboxyethyl)phosphine (TCEP) and its salts—see Analytical Biochemistry 273, 73-80 (1999).
- TCEP tris(2-carboxyethyl)phosphine
- Other known disulfide-reducing agents such as dithiothreitol, 2-mercaptoethanol, cysteamine, and dithiobutylamine (J M Perkel, Chem. Eng'g News , Feb.
- the linking groups L 1 , L 2 and L 3 can be any suitable organic linkages that connect T 1 and T 2 to A, and connect A to the payload R.
- Suitable examples of L 1 and L 2 include [T]-(CH 2 ) 1-6 -[A]; [T]-(CH 2 ) 1-6 C( ⁇ O)-[A]; [T]-(CH 2 ) 1-6 C( ⁇ O)—NH—[A]; [T]-CH 2 C( ⁇ O)—O—[A]; [T]-(CH 2 CH 2 O) n -[A]; [T]-Phenyl-C(O)NH-[A], and combinations of these, where n is typically 1-20, and [T] and [A] respectively indicate which end of the linker is attached to group T 1 or T 2 , and which end connects to group A.
- linkages for L 3 include [A]-C( ⁇ O)—(CH 2 ) 1-6 —[R]; [A]-CH 2 C( ⁇ O)—[R]; [A]-CH 2 C( ⁇ O)—NH—[R]; [A]-CH 2 C( ⁇ O)—O—[R]; [A]-(CH 2 CH 2 O) n —[R]; [A]-Phenyl-C(O)NH—[R], and the like, where n is typically 1-20, and [A] and [R] respectively indicate which end of the linker is attached to group A, and which end connects to payload R.
- the linker L 3 can have two payloads attached to increase payload loading on the conjugate. In other embodiments, the linker L 3 can have three payloads attached to increase payload loading on the conjugate. Where more than one payload is attached to a given linker the payloads can be the same or different.
- Suitable linkers also include combinations of the components of these groups: the nature of the linkers is not critical to the practice of the invention and can be based on convenience and availability of methods for attachment to at least one payload R, or on desired physicochemical properties for the conjugate, or on its intended use.
- linker L 1 , L 2 and L 3 may also comprise one or more components selected from the following groups:
- a peptide comprising 1 to 100 amino acids, preferably 1-30 or 1-6 amino acids.
- L 3 can be or can comprise a cleavable linker such as Val-Cit (valine-citrulline, a dipeptide that is selectively cleaved by cathepsin B), or val-cit-PABC (valine-citrulline p-aminobenzylcarbamate, see Bioconjugate Chem. 19(10), 1960-63 (2008)), a disulfide, or a linker cleaved by glucuronidase, such as the linker present in this formula:
- Val-Cit valine-citrulline, a dipeptide that is selectively cleaved by cathepsin B
- val-cit-PABC valine-citrulline p-aminobenzylcarbamate, see Bioconjugate Chem. 19(10), 1960-63 (2008)
- a disulfide or a linker cleaved by glucuronidase, such as the linker present in this formula:
- [A] indicates a point of attachment to group A in Formula (I)
- [R] represents a point of attachment to payload R.
- Such cleavable linkers would preferably be used as L 3 in Formula (I), but may also be used as L 1 and/or L 2 .
- the Payload (R) can be any moiety that is useful to attach to a protein.
- Many examples of compounds that can be usefully attached to proteins are known in the art. Examples include label moieties that enable a user to locate or identify the protein, including chelators that bind metal ions to provide detectability of the conjugate; binding moieties such as biotin or avidin, polynucleotides, antibodies or fragments thereof, poly-Arg or poly-lys containing 5-15 amino acid residues, etc., that make it easy to purify or isolate the protein or affix it to a surface; property-modifying groups such as fatty acid groups or polyethylene glycol (PEG); antigenic groups such as polysaccharides or cell surface proteins that are characteristic of a particular type of cell or bacterium; coupling groups that enable the modified protein or peptide to be attached to another molecule to make more complex conjugates, such as bispecific antibodies (see FIG.
- hitchhiking compounds including pharmaceutical compounds and radionuclides as well as cytotoxins, which can hitchhike on the protein to a desired tissue or cell where they can produce a desired effect.
- hitchhiking compounds may act while they remain conjugated to the protein or a portion thereof, or they may first detach from the protein if the linking group is one that can readily cleave in vivo.
- Suitable pharmaceutical payloads for use with these methods include microtubule inhibitors, topoisomerase I inhibitors, intercalating agents, inhibitors of intracellular signaling pathways, kinase inhibitors, and DNA minor groove binders, including compound classes such as maytansinoids, auristatins, calicheamycins, psymberins, duocarmycins, anthracyclins, camptothecins, doxorubicins, taxols, pyrrolobenzodiazepines, and the like.
- compound classes such as maytansinoids, auristatins, calicheamycins, psymberins, duocarmycins, anthracyclins, camptothecins, doxorubicins, taxols, pyrrolobenzodiazepines, and the like.
- these pharmaceutical payloads having therapeutic or diagnostic uses include paclitaxel, docetaxel, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, mithramycin, actinomycin, glucorticoids, puromycin, epirubicin, cyclophosphamide, methotrexate, cytarabine, f-fluorouracil, platins, streptozotocin, minomycin C, anthracyclines, dactinomycin or actinomycin, bleomycin, mithramycin, anthramycin, duocarmycins, ifosfamide, mitoxantrone, daunomycin, carminomycin, animoterin, melphalan, esperamicins, lexitropsins, auristatins (e.g., auristatin E, auristatin F, A
- Suitable coupling groups that can be used as payloads include maleimide, thiols, alpha-halo ketones (e.g., —C( ⁇ O)—CH 2 —X where X is chloro, bromo or iodo), carboxylic acids, amines, hydroxyls, alkenes, alkynes including cyclic octynes that can be used in copper-free ‘click’ chemistry, azide, and the like.
- ‘Complementary’ coupling groups are two coupling groups that readily combine to form a covalent bond, such as the pairs mentioned above (carboxylate plus amine to form an amide; azide plus alkyne to form a 1,2,3-triazole; maleimide plus thiol, where the thiol adds to the double bond via a Michael addition; alpha-halo ketone plus thiol which form an alpha-thio ketone by alkylation of the thiol; etc.)
- a coupling group to serve as a Payload (R) is selected from the group consisting of halogen, —C ⁇ CH, —C ⁇ CH 2 , —OH, —SH, —SO 2 —CH ⁇ CH 2 , —O—NH 2 , —N 3 , —O—P(O)(OH) 2 , —C(O)—H, —C(O)—CH 3 , —NH—C(O)—CH 2 —
- a polypeptide-payload conjugate comprising:
- each of T 1 and T 2 comprises a chain of three carbon atoms connecting the attached sulfur atoms.
- T 2 represents a group of the formula —CH 2 —C( ⁇ N—O-[L 2 ])-CH 2 —, wherein [L 2 ] indicates the point of attachment of T 2 to L 2 .
- polypeptide-payload conjugate of any of embodiments 1-6 wherein the polypeptide is an antibody or antibody Fc, and the two sulfur atoms attached to T 1 formed a disulfide bind in the unconjugated antibody or antibody Fc.
- R is a therapeutic agent, a detectable label, or a functional group selected from N 3 , COOH, NH 2 , SH, —S—Ar, maleimide, and HC ⁇ C—, where Ar represents phenyl or pyridyl;
- L 1 , L 2 and L 3 are linking groups
- L 3 comprises at least one group selected from —(CH 2 ) 1-6 —, —(CH 2 CH 2 O) 1-6 — and —(OCH 2 CH 2 ) 1-6 —.
- R-L 3 - is of the formula R—Z—C( ⁇ O)—, wherein Z comprises at least one group selected from —(CH 2 ) 1-6 —, —(CH 2 CH 2 O) 1-6 — and —(OCH 2 CH 2 ) 1-6 —.
- a pharmaceutical composition comprising the polypeptide-payload conjugate of any of embodiments 1-11 and at least one pharmaceutically acceptable carrier, diluent, or buffer.
- a payload can be attached by suitable methods, such as oxime formation when the tether contains a reactive ketone.
- suitable methods such as oxime formation when the tether contains a reactive ketone.
- a bis-aminooxy compound containing the payload can be added in one step; alternatively, an alkoxyamine having a functional group can be added to the tether, and the functional group can be used to attach the payload in a subsequent step.
- the eluted Fc was buffer exchanged to PBS pH 7.4 using Amicon 10K MWCO centrifugal filters to give Fc (700 ⁇ L, 19.6 mg/mL, 13.7 mg, 77%).
- LCMS ESI (after deglycosylation with PNGase F): 50410.
- N,N-bis(1-(aminooxy)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-yl)-1-azido-3,6,9,12-tetraoxapentadecan-15-amide (4, 1.81 ⁇ L of a 30 mg/mL solution in DMSO, 54 ⁇ g, 0.060 ⁇ mol), and 3,5-diaminobenzoic acid in DMSO (2.28 ⁇ L, 3.00 ⁇ mol) were added sequentially to the modified anti-Her2 IgG (13, 441 ⁇ g, 0.003 ⁇ mol) in 38 ⁇ L of PBS (pH 7.4) at room temperature.
Abstract
Description
- This application is a divisional of parent application U.S. application Ser. No. 15/312,267, filed 18 Nov. 2016, which is a 371 U.S. national phase application of international application number PCT/US2015/032126 filed 22 May 2015, which application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62/002,585, filed 23 May 2014. The disclosures of which are incorporated herein by reference in their entirety and for all purposes.
- A wide variety of chemical moieties (‘payloads’) have been covalently attached to enzymes, antibodies, and other polypeptides or proteins, to form conjugates. The payloads may be used to locate the protein to which they are attached (e.g., labels), to modify the physicochemical properties or stability of the protein (e.g., PEGylation), to enable the protein to be attached to another molecule or protein (functional or coupling groups, for connecting the conjugate to another compound or another conjugate), or to modify the function or activity of the payload or the protein (e.g., vaccine conjugates). The protein may also act as a carrier to deliver the attached payload to a particular tissue or cell type, such as in antibody-drug conjugates (ADCs). Classes of payloads that can be usefully linked to proteins include detectable moieties (labels), anchoring moieties to attach the protein to a surface or another compound, antigens that elicit an immune response when conjugated to a protein, coupling groups that react readily with a chemically complementary coupling partner (thus connecting the protein to another entity), and therapeutic moieties such as cytotoxins and other bioactive agents.
- Attaching these diverse structures to proteins in a controlled and reproducible fashion is often critical for the conjugates to function correctly, particularly when they are used as therapeutic agents. In ADCs, for example, it is important to carefully control the number of payload compounds attached to an antibody, which is not easy since the carrier is a large and complex protein. For example, depending on the particular target, linker, and cytotoxin, the optimum DAR (drug to antibody ratio) for an ADC may vary from 1 to 6 or more, in order to balance factors such as efficacy, stability, and safety. If ADCs are made as mixtures with varying drug/antibody ratios (DARs), separation is difficult, and consistency of the product is important for both therapeutic and regulatory reasons. Thus there is a need for methods to produce ADCs with good control of drug-antibody ratios, as well as efficient conjugation and consistent placement of the payload attachment point.
- A number of methods have been developed for attaching payloads to proteins to address some of these issues. See, e.g., Sletten, E. M. and Bertozzi, C. R. Angew. Chem. Int. Ed. 2009, 48, 6974-6998; Basle′, E.; Joubert, N.; Pucheault, M. Chemistry & Biology 2010, 17, 213-227; and Hermanson, G. T. Bioconjugate Techniques, 2nd ed.; Academic Press: San Diego, Calif., 2008. The most common conjugation methods rely on the chemical reactivity of certain amino acids that occur naturally in many natural proteins: lysine and cysteine are often used, because they provide a reactive site for connecting the payload to the protein. Proteins often have more lysines than the optimum number of payloads to be attached, though: adding enough payload moieties to occupy all of the available lysines in order to produce a consistent, homogenous product may add too many payload molecules for optimum efficacy, while partial loading typically provides a heterogeneous product, which can be problematic for a variety of reasons—in the case of Mylotarg™, the first commercialized ADC, for example, the heterogeneity of the ADC product seems likely to have contributed to the issues that led to a decision to withdraw the product from registration. Fuenmayor, et al., Cancers, vol. 3, 3370-93 (2011).
- The frequency of occurrence of cysteine in natural proteins is lower than that of lysine, and cysteine may be suitable for use as a site for conjugation where it is available in adequate numbers; where too few cysteines are present, one or more may be inserted by standard protein modification methods. However, it is often preferable to avoid modifying the sequence of the natural protein by inserting a cysteine or by removing a disulfide. While it is not difficult to convert a disulfide into two free cysteines by reducing the disulfide, doing so may disrupt the secondary or tertiary structure of the protein.
- Some methods for inserting a tether between cysteine residues formed by reducing a disulfide on a protein have been reported. This approach is particularly appealing for ADC production, because the typical antibody structure contains four reducible inter-chain disulfides that can be utilized without protein engineering. One method used for such conjugation involves a sulfone-substituted methacrylate derivative. US2006/0210526. This method forms a reactive intermediate that requires an elimination step before alkylation of the second sulfur atom occurs. The conditions for that multi-step process can result in incomplete formation of a linker (tether) between cysteines, and the reaction conditions can cause protein denaturation. Another approach uses a maleimide derivative, e.g., a 3,4-dibromomaleimide. WO2011/018613.
- However, the conjugate formed in this process can suffer from stability problems because the Michael addition of the thiols on the maleimide ring is reversible, so the tether between the sulfur atoms or the payload itself can be lost. Thus novel methods are needed that turn disulfide groups into conjugation sites without giving up the stabilizing effect of the inter-chain disulfides, while also providing efficient conjugation, stability, and consistent payload/protein ratios. The present invention provides useful methods for making such ADCs.
- In one aspect, the invention provides a method to use two disulfides on an antibody to link a payload to the protein, forming a protein conjugate. The method involves reducing the disulfides to provide free thiol groups, and tying two thiol groups together with a bridging group that keeps them in about the same positions they occupied when they formed a disulfide. Keeping the cysteine groups in their same approximate positions minimizes any adverse effect on the protein's conformation that may occur upon reduction of the disulfide. The tether that is introduced to link the two thiol groups together contains a reactive functional group that can be used to attach a payload of interest. In some embodiments, the tether contains a carbonyl group that is reactive enough to form an oxime linkage with a hydroxylamine group, and the payload is conjugated to the activated protein by forming such linkage. For example, the reduced protein can be reacted with a 1,3-dihalo acetone such as dichloroacetone or dibromoacetone, thereby inserting a 3-carbon tether connecting the two sulfur atoms together. This may suitably simulate the effect of the disulfide, keeping the protein in a conformation very similar to the one it had when the disulfide was present, while it also provides greater stability than the disulfide as well as a place to attach a payload. The tethers used in the methods and compositions of the invention provide a chemically reactive functional group, and a protein containing this type of tether between two cysteine sulfur atoms is referred to herein as an activated protein. While each ketone can be used to attach a payload, in the present invention two such ketones or other tethering groups are connected together with a bridging group that provides a new point of attachment for a payload. As a result of using two S—S tethers to attach a bridging group that carries one payload, the number of payload compounds on a given polypeptide is one-half of the number of disulfides used in the conjugation method. The Figures herein provide a schematic representation of the conjugates of the invention. Other methods of using disulfides to form conjugates are described in WO/2014/083505 and PCT/IB2014/066300. The entire contents of WO/2014/083505 and PCT/IB2014/066300 and their priority documents are expressly incorporated herein by reference for all purposes.
- These methods can be applied to any protein having two or more accessible disulfide linkages, and are typically useful for natural proteins having a molecular weight above 500 Da and typically above 2,000 Da, where a disulfide is present in the native or active form of the protein.
- The methods can be used with proteins containing more than one disulfide, such as 2-10, or typically up to 6 disulfide groups, at least two of which are sufficiently accessible to be reduced by conventional disulfide reducing agents. These methods produce a conjugate containing at least one payload for each pair of disulfide groups that are utilized, and the conjugate substantially retains the native or active conformation of the protein.
-
FIG. 1 is a scheme illustrating how a disulfide can be activated and used to make a polypeptide-payload conjugate. -
FIG. 2 provides a diagram of a generic antibody, illustrating the presence and position of the inter-chain disulfides that can be used in the methods of the invention for forming conjugates. -
FIGS. 3A, 3B and 3C represent the subunits of an antibody with disulfides, that are then used to make an activated polypeptide, and a polypeptide-payload conjugate of the invention. -
FIG. 4 shows the SDS-PAGE gel of the Fc, 12, and 14 (Example 1). -
FIG. 5 shows the SDS-PAGE gel of the products of Example 2. -
FIG. 6 shows the SDS-PAGE gel of the products of Examples 4 and 5. - ‘Protein’ and polypeptide as used herein refer to peptides containing ten or more amino acid residues connected by amide (peptide) bonds. A protein or polypeptide may be a single continuous strand or it may include two or more strands that associate naturally to form a stable complex, and may be or comprise a cyclic polypeptide. Typically the proteins described herein comprise mainly or only naturally occurring amino acids, though the methods described herein are equally useful with polypeptides that contain one or more non-natural amino acids. Commonly (but not necessarily) the amino acids are mostly or entirely of the L configuration and are selected from the common ‘essential’ amino acids. The methods are also suitable for use with polypeptide complexes that contain two or more peptide chains, where the disulfide bonds used for the methods of the invention may be inter-chain or intra-chain disulfides.
- EDT Ethane dithiol
HBTU N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate
MeCN acetonitrile
NMP N-methyl pyrrolidinone
PBS Phosphate-buffered saline - TFA Trifluoroacetic acid
TIPS Triisopropyl silane - An example of one embodiment of the invention is shown in
FIGS. 3A-3C . The Figure depicts a generic antibody schematically, showing four inter-chain disulfide bonds. In one embodiment the inter-chain disulfides are all reduced, forming a reduced protein having eight free thiols derived from the disulfides. The reduced polypeptide is then allowed to react with a dihaloacetone or similar bis-electrophile (e.g., 1, 3-dichloroacetone or 1,3-dibromoacetone) to form an activated protein wherein each pair of thiols is linked together through a functionalized tether: the tether in this example contains a free ketone group that is reactive toward Schiff base formation. A bis-alkoxyamine bridging group is then allowed to react with the ketones of the activated polypeptide, wherein a single payload group is attached to the bridging group. - The methods of the invention can also be used with other tethering groups between sulfur atoms from a disulfide. For example, methods to tie together sulfhydryl groups using cyclic groups are known in the art, using dibromomaleimide with a payload attached to the ring nitrogen. These can be adapted to produce conjugates of the invention by tying to of the linker moieties together to form a bridge that carries one payload compound, as depicted here. This double-attachment should also reduce potential problems caused by reversible Michael addition of S onto the maleimide ring, which can release the payload (cytotoxin) prematurely. In the conjugate attached at four sulfur atoms, the risk of premature release of payload should be reduced.
- Similarly, methods for using a pair of sulfur atoms to link a payload by Michael addition/elimination from a substituted methacrylate are known in the art, and can be adapted to provide conjugates of the invention. Instead of linking one payload through the carboxylate of a methacrylate, two methacrylate groups can be bridged together either before or after conjugation to the protein as shown here.
- The methods of the invention are suitable for use to form conjugates from most polypeptides that contain at least two disulfide linkages that can be reduced without denaturing the protein, or that contain four or more free cysteine residues that can be connected in pairs by reaction with a 1,3-dihaloacetone reactant. Typically, the polypeptide is one where the thiols react with dichloroacetone or dibromoacetone under conditions described herein to produce at least 50% cross-linking of the two thiols, and frequently the extent of cross-linking is at least about 70%, 80% or 90%.
- A pair of cysteines to be linked together may be on a single polypeptide strand, or they may be on separate polypeptide strands that form a polypeptide complex. In certain embodiments, the methods utilize a protein or polypeptide having 2-6 disulfide linkages, or 4-8 free cysteine residues, and involve reduction of at least two of the disulfides. The disulfide-containing polypeptide can be any polypeptide having at least 10 amino acid residues, preferably at least 50 amino acids, that contains a pair of disulfide linkages within a single polypeptide sequence, including a polypeptide complex where a disulfide (or two or more disulfides) connects one polypeptide sequence to another amino acid or polypeptide, provided the complex does not dissociate rapidly when the disulfides are reduced for insertion of the tether between the sulfur atoms. Typical proteins for use in the methods of the invention include cyclic peptides and linear peptides containing about 50 to about 5000 amino acids, typically at least 100 amino acids and up to about 2000, including functional proteins such as enzymes or receptors; protein complexes having at least two disulfide linkages (often connecting two separate polypeptide strands); structural proteins; proteins used as vaccine scaffolds such as CRM197 or other proteins having adjuvant activity; and particularly antibodies or antibody fragments having at least two reducible disulfide bonds, e.g., Fc. Particularly useful proteins for these methods include antibodies, especially monoclonal antibodies including engineered antibodies, modified antibodies and antibody fragments having two inter-chain disulfides; vaccine carrier proteins such as CRM197; and single-stranded proteins having at least two disulfide linkages or at least four cysteine residues and having a molecular weight between 500 and 500,000, typically between 1,000 and 200,000. Methods for engineering an antibody or other protein to introduce two or more cysteine residues, for example, and for modifying antibodies are well known in the art.
- The methods are especially useful with antibodies and antibody subunits containing at least two reducible disulfides, including IgG and Fc, which have two to four accessible inter-strand disulfide bonds that are readily reduced by methods known in the art.
- The disulfide linkages of disulfide-containing proteins for use in the methods and compositions of the invention are reduced to form four or more free thiol groups: methods for such reduction are well known in the art. In some embodiments, the reduction is performed using a reducing agent that selectively reduces disulfide linkages that are readily accessible to solvent around the protein: one suitable reducing agent is tris(2-carboxyethyl)phosphine (TCEP) and its salts—see Analytical Biochemistry 273, 73-80 (1999). Other known disulfide-reducing agents such as dithiothreitol, 2-mercaptoethanol, cysteamine, and dithiobutylamine (J M Perkel, Chem. Eng'g News, Feb. 29, 2012; Lukesh, et al., J. Am. Chem. Soc., 134, 4057-59 (2012)) and trialkyl phosphines such as tributyl phosphine (WO2008/157380) can also be used.
- The linking groups L1, L2 and L3 can be any suitable organic linkages that connect T1 and T2 to A, and connect A to the payload R. Suitable examples of L1 and L2, which may be the same or different, include [T]-(CH2)1-6-[A]; [T]-(CH2)1-6C(═O)-[A]; [T]-(CH2)1-6C(═O)—NH—[A]; [T]-CH2C(═O)—O—[A]; [T]-(CH2CH2O)n-[A]; [T]-Phenyl-C(O)NH-[A], and combinations of these, where n is typically 1-20, and [T] and [A] respectively indicate which end of the linker is attached to group T1 or T2, and which end connects to group A. Some examples of suitable linkages for L3 include [A]-C(═O)—(CH2)1-6—[R]; [A]-CH2C(═O)—[R]; [A]-CH2C(═O)—NH—[R]; [A]-CH2C(═O)—O—[R]; [A]-(CH2CH2O)n—[R]; [A]-Phenyl-C(O)NH—[R], and the like, where n is typically 1-20, and [A] and [R] respectively indicate which end of the linker is attached to group A, and which end connects to payload R. In some embodiments, the linker L3 can have two payloads attached to increase payload loading on the conjugate. In other embodiments, the linker L3 can have three payloads attached to increase payload loading on the conjugate. Where more than one payload is attached to a given linker the payloads can be the same or different. Suitable linkers also include combinations of the components of these groups: the nature of the linkers is not critical to the practice of the invention and can be based on convenience and availability of methods for attachment to at least one payload R, or on desired physicochemical properties for the conjugate, or on its intended use. Selection of suitable linkers is within the level of ordinary skill and depends on the structure of the Payload R and available methods for modifying it to attach linker L3 as well as whether the planned use makes it desirable to use a cleavable linker. Typically the linker is attached at one or both ends via an amide or ester group; frequently the linker L contains a peptide bond or ester to allow in vivo lysis by protease or esterase activities (for example val-cit, a dipeptide that is cleaved by cathepsin B, or Gly-phe-leu-gly, which is also cleavable by cathepsin B); optionally it contains one or more ethylene oxide units (—OCH2CH2—); and in many embodiments it contains at least one and up to six amino acid moieties. Suitable embodiments of linkers L1, L2 and L3 may also comprise one or more components selected from the following groups:
- (a) a bond, —O—, —S—, —S—S—, —NH—, —N((C1-C6)alkyl)-, —NH—C(O)—NH—, —C(O)—NH—, —NH—C(O)—;
- (b) (C1-C20)alkylene, (C2-C20)alkenylene, (C2-C20)alkynylene, —Z—(C1-C20)alkylene-, —Z—(C2-C20)alkenylene, —Z—(C2-C20)alkynylene, (C1-C20)alkylene-Z—(C1-C20)alkylene, (C2-C20)alkenylene-Z—(C2-C20)alkenylene, (C2-C20)alkynylene-Z—(C2-C20)alkynylene, where Z is —C(O)—, —NH—, —N(C1-C6)alkyl)-, —NH—C(O)—NH—, —C(O)—NH—, —NH—C(O)—, (C3-C7)cycloalkylene, phenylene, heteroarylene, or heterocyclene and where said (C1-C20)alkylene, said (C2-C20)alkenylene, and said (C2-C20)alkynylene moieties each independently optionally contain one or more oxygen atoms interdispersed within said moieties, such that the oxygen atoms are separated by at least one and preferably two carbon atoms;
- (c) (C3-C7)cycloalkylene, (C3-C7)cycloalkylene-Y—(C3-C7)cycloalkylene, —Y—(C3-C7)cycloalkylene, phenylene, —Y-phenylene, phenylene-Y-phenylene, heteroarylene, Y-heteroarylene, heteroarylene-Y-heteroarylene, heterocyclene, —Y-heterocyclene, or heterocyclene-Y-heterocyclene, where Y is (C1-C20)alkylene, (C2-C20)alkenylene, (C2-C20)alkynylene, —O—, —C(O)—, —S—, —NH—, —N((C1-C6)alkyl)-, —NH—C(O)—NH—, —C(O)—NH—, or —NH—C(O)— and where said (C3-C7)cycloalkylene, said phenylene, said heteroarylene, and said heterocyclene moieties are each individually optionally substituted with 1 to 3 substituents selected from halo, (C1-C4)alkyl or halo-substituted(C1-C4)alkyl;
- (d) —[OCH2CH2]v—, where v is 1-20, preferably 1-10; and
- (e) a peptide comprising 1 to 100 amino acids, preferably 1-30 or 1-6 amino acids.
- Furthermore, L3 can be or can comprise a cleavable linker such as Val-Cit (valine-citrulline, a dipeptide that is selectively cleaved by cathepsin B), or val-cit-PABC (valine-citrulline p-aminobenzylcarbamate, see Bioconjugate Chem. 19(10), 1960-63 (2008)), a disulfide, or a linker cleaved by glucuronidase, such as the linker present in this formula:
- where [A] indicates a point of attachment to group A in Formula (I), and [R] represents a point of attachment to payload R. (ACS Med. Chem. Letters, vol. 1, 277-280 (2010). Such cleavable linkers would preferably be used as L3 in Formula (I), but may also be used as L1 and/or L2.
- The Payload (R) can be any moiety that is useful to attach to a protein. Many examples of compounds that can be usefully attached to proteins are known in the art. Examples include label moieties that enable a user to locate or identify the protein, including chelators that bind metal ions to provide detectability of the conjugate; binding moieties such as biotin or avidin, polynucleotides, antibodies or fragments thereof, poly-Arg or poly-lys containing 5-15 amino acid residues, etc., that make it easy to purify or isolate the protein or affix it to a surface; property-modifying groups such as fatty acid groups or polyethylene glycol (PEG); antigenic groups such as polysaccharides or cell surface proteins that are characteristic of a particular type of cell or bacterium; coupling groups that enable the modified protein or peptide to be attached to another molecule to make more complex conjugates, such as bispecific antibodies (see
FIG. 2 ); and bioactive compounds including pharmaceutical compounds and radionuclides as well as cytotoxins, which can hitchhike on the protein to a desired tissue or cell where they can produce a desired effect. These hitchhiking compounds may act while they remain conjugated to the protein or a portion thereof, or they may first detach from the protein if the linking group is one that can readily cleave in vivo. Suitable pharmaceutical payloads for use with these methods include microtubule inhibitors, topoisomerase I inhibitors, intercalating agents, inhibitors of intracellular signaling pathways, kinase inhibitors, and DNA minor groove binders, including compound classes such as maytansinoids, auristatins, calicheamycins, psymberins, duocarmycins, anthracyclins, camptothecins, doxorubicins, taxols, pyrrolobenzodiazepines, and the like. - Specific examples of these pharmaceutical payloads having therapeutic or diagnostic uses include paclitaxel, docetaxel, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, mithramycin, actinomycin, glucorticoids, puromycin, epirubicin, cyclophosphamide, methotrexate, cytarabine, f-fluorouracil, platins, streptozotocin, minomycin C, anthracyclines, dactinomycin or actinomycin, bleomycin, mithramycin, anthramycin, duocarmycins, ifosfamide, mitoxantrone, daunomycin, carminomycin, animoterin, melphalan, esperamicins, lexitropsins, auristatins (e.g., auristatin E, auristatin F, AEB, AEVB, AEFP, MMAE, MMAF), eleuthorobin, netropsin, podophyllotoxins, maytansiods including maytansine and DM1, and combretestatins.
- Suitable coupling groups that can be used as payloads (groups that can be used to couple the conjugate to another moiety) include maleimide, thiols, alpha-halo ketones (e.g., —C(═O)—CH2—X where X is chloro, bromo or iodo), carboxylic acids, amines, hydroxyls, alkenes, alkynes including cyclic octynes that can be used in copper-free ‘click’ chemistry, azide, and the like. Methods to use these coupling groups to connect the conjugates of the invention to other compounds having complementary coupling groups are well known in the art, and include Michael addition of a thiol to a maleimide, alkylation of a thiol with an alpha-haloketone, amide bond formation between amine and a carboxylic acid, ‘click’ chemistry (see, e.g., Meldal, et al., Chem Rev., vol 108, 2952-3015 (2008)) to link an azide to an alkyne by forming a 1,2,3-triazole ring, and ‘copper-free click’ chemistry. See e.g., Meeuwissen, et al. Polymer Chemistry, vol. 3, 1783-95 (2012). ‘Complementary’ coupling groups are two coupling groups that readily combine to form a covalent bond, such as the pairs mentioned above (carboxylate plus amine to form an amide; azide plus alkyne to form a 1,2,3-triazole; maleimide plus thiol, where the thiol adds to the double bond via a Michael addition; alpha-halo ketone plus thiol which form an alpha-thio ketone by alkylation of the thiol; etc.) In particular examples, a coupling group to serve as a Payload (R) is selected from the group consisting of halogen, —C≡CH, —C═CH2, —OH, —SH, —SO2—CH═CH2, —O—NH2, —N3, —O—P(O)(OH)2, —C(O)—H, —C(O)—CH3, —NH—C(O)—CH2—I, maleimidyl, 3,5-dioxo-1,2,4-triazolidin-4-yl, 1H-pyrrole-2,5-dione-1-yl, pyridin-2-yl-disulfanyl, tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one-4-yl, 1-carbonyloxy-2,5-dioxopyrrolidine, sodium 1-carbonyloxy-2,5-dioxopyrrolidine-3-sulfonate, —SSR1, —C(O)—OR1, —N(R1)H, —NH—N(R1)H, where R1 is H or (C1-C6)alkyl, and —C(O)—R2, where R2 is H, (C1-C4)alkyl, halo-substituted(C1-C4)alkyl, —CH═CH2, N(R1)H, or —NH—N(R1)H.
- The following enumerated embodiments illustrate particular aspects of the invention.
- 1. A polypeptide-payload conjugate comprising:
-
- wherein the circle represents a polypeptide or polypeptide complex, which may comprise modifications other than the one shown;
- each S is a sulfur atom of a cysteine residue of the polypeptide or polypeptide complex;
- T1 and T2 each represent a tether that connects two sulfur atoms through 1-5 carbon atoms, wherein T1 also attaches to L1 and T2 also attaches to L2;
- L1 and L2 each represent a linking group connecting T1 or T2, respectively, to A;
- L3 is a linking group that connects A to R;
- A represents a group connecting L1, L2 and L3;
- and R represents a payload or a reactive functional group for attaching a payload.
- 2. The polypeptide-payload conjugate of
embodiment 1, wherein the polypeptide is an antibody or an antibody Fc. - 3. The polypeptide-payload conjugate of
embodiment - 4. The polypeptide-payload conjugate of any of embodiments 1-3, wherein T1 represents a group of the formula —CH2—C(═N—O-[L1])-CH2—, wherein [L1] indicates the point of attachment of T1 to L1.
- 5. The polypeptide-payload conjugate of any of embodiments 1-4, wherein T2 represents a group of the formula —CH2—C(═N—O-[L2])-CH2—, wherein [L2] indicates the point of attachment of T2 to L2.
- 6. The polypeptide-payload conjugate of any of embodiments 1-5, wherein L1 and L2 are the same.
- 7. The polypeptide-payload conjugate of any of embodiments 1-6, wherein the polypeptide is an antibody or antibody Fc, and the two sulfur atoms attached to T1 formed a disulfide bind in the unconjugated antibody or antibody Fc.
- 8. The polypeptide-payload conjugate of any of embodiments 1-7, wherein the polypeptide is an antibody or antibody Fc, and the two sulfur atoms attached to T2 formed a disulfide bind in the unconjugated polypeptide.
- 9. The polypeptide-payload conjugate of any of embodiments 1-8, wherein R represents a therapeutic agent, a detectable label, an antigen, or a binding group.
- 10. The polypeptide-payload conjugate of embodiment 9, wherein R represents a cytotoxin.
- 11. The polypeptide-payload conjugate of any of embodiments 1-10, wherein A is N, CH, phenyl, C3-6 cycloalkyl, or a 5-6 membered heterocyclic or heteroaryl group having up to two heteroatoms selected from N, O and S as ring members.
- 12. The polypeptide-payload conjugate of any of embodiments 1-11, which is of the formula
- wherein the circle represents an antibody.
- 13. A compound of the formula (IIa)
- wherein R is a therapeutic agent, a detectable label, or a functional group selected from N3, COOH, NH2, SH, —S—Ar, maleimide, and HC≡C—, where Ar represents phenyl or pyridyl;
- L1, L2 and L3 are linking groups; and
- A is N, CH, phenyl, C3-6 cycloalkyl, or a 5-6 membered heterocyclic or heteroaryl group having up to two heteroatoms selected from N, O and S as ring members;
- or a salt thereof.
- 14. The compound of embodiment 13, wherein L1 and L2 are the same.
- 15. The compound of
embodiment 13 or 14, wherein R is a cytotoxin. - 16. The compound of
embodiment 13 or 14, wherein L3 comprises at least one group selected from —(CH2)1-6—, —(CH2CH2O)1-6— and —(OCH2CH2)1-6—. - 17. The compound of any one of embodiments 13-16, which is of the formula
- where R3 is H or (C1-C6)alkyl.
- 18. The compound of any one of embodiments 13-17, wherein R-L3- is of the formula R—Z—C(═O)—, wherein Z comprises at least one group selected from —(CH2)1-6—, —(CH2CH2O)1-6— and —(OCH2CH2)1-6—.
- 19. A method to prepare a polypeptide-payload conjugate, which comprises contacting an activated polypeptide or polypeptide complex of formula (IIIa) or (IIIb):
-
- wherein the circle represents a polypeptide or polypeptide complex, which is activated by the inserted carbonyl groups, and each S represents a sulfur atom of a cysteine residue comprised in the polypeptide or polypeptide complex,
- with the compound of any one of embodiments 13-18.
- 20. The method of embodiment 19, wherein the polypeptide or polypeptide complex is an antibody or an Fc portion of an antibody.
- 21. The method of embodiment 19 or 20, which further comprises a step of preparing the activated polypeptide or polypeptide complex by a method that comprises reducing at least two disulfide bonds of an antibody or antibody Fc to make a reduced polypeptide or polypeptide complex,
- and contacting the reduced polypeptide or polypeptide complex with dichloroacetone to provide the activated polypeptide or polypeptide complex.
- 22. A pharmaceutical composition comprising the polypeptide-payload conjugate of any of embodiments 1-11 and at least one pharmaceutically acceptable carrier, diluent, or buffer.
- The methods of the invention involve reducing a disulfide of a protein to be modified, forming a reduced protein that contains two free thiol groups. The reduced protein is contacted with a functionalized tethering compound that is capable of reacting with both of the free thiols on the reduced protein to tether the free thiols together, while also retaining at least one functional group on the tether that is suitable for conjugation; or alternatively the group to be attached may already be connected to the tethering group before the tethering group is added to the protein. In some embodiments, the functional group on the tether is a carbonyl group, e.g., the ketone obtained when the free thiols are allowed to react with a 1,3-dihaloketone (see
FIG. 1 ). - Because the free thiols are strongly nucleophilic, they react readily with electrophiles such as alkyl halides or alkyl tosylates, via irreversible reactions that involve displacing a leaving group and forming a covalent sulfur-carbon bond. Some suitable examples of functionalized carbonyl-containing tethering compounds include 1,3-dichloroacetone and 1,3-dibromoacetone. These reagents have been used to provide stabilization of disulfide moieties in small cyclic peptides by tethering sulfhydryls together. See e.g. WO2008/157380 (reaction of dichloroacetone with a reduced cyclic pentapeptide, followed by reduction of the carbonyl). Sulfonates of 1,3-dihydroxyacetone (e.g., mesylate, triflate, phenylsulfonate, tosylate, and the like) can also be used. These reagents are sufficiently reactive toward the free thiols of a reduced protein to provide reasonably rapid reaction to form an activated protein with two cysteine residues tethered together, wherein each of the free thiols is covalently attached to the functionalized tethering group.
- The reduced protein and functionalized tethering compound are contacted under conditions suitable to promote reaction between the tethering compound and the two free thiols of the reduced protein, and particularly under conditions of concentration and temperature that favor causing both of the free thiols that were previously joined in a disulfide bond to react with a single molecule of the tethering compound so they are once again tied together, but now with a short tether connecting them instead of a direct disulfide bond. This reaction forms an activated protein as illustrated in
FIG. 1 , having a functionalized tether [—CH2C(O)—CH2-] between the two sulfur atoms. The tether inFIG. 1 includes a carbonyl that can be used to efficiently attach a payload via clean and efficient Schiff base formation chemistry. - For the present invention, at least two disulfides are reduced and used for conjugation. When the tethering group contains a reactive ketone to serve as the conjugation site, as depicted in
FIG. 1 , the protein will typically be activated with two tethering groups, which will ordinarily be the same. The two activated tethering groups will then be linked together by reaction with a bridging reagent having two aminooxy groups-seeFIG. 3 . The bridging group then provides an attachment point for a payload. - It is understood throughout this discussion that the protein, even though it is depicted as a circle or sphere, can be a small polypeptide of fewer than 10 amino acids or a large enzyme or a complex of two or more subunits or polypeptide strands. The two sulfur atoms of the disulfide can be on one subunit of a multimeric complex, or they can be on different strands of a protein complex. In addition to the disulfide participating in the transformations described herein, the protein may also contain other disulfide linkages that may be reduced, or may not be reduced due to their location within the protein. The methods of the invention can utilize known methods to selectively reduce solvent-accessible disulfide linkages near the surface of the folded protein, often without reducing ‘buried’ disulfides that may be essential for maintaining the overall shape and functionality of the protein, or for keeping two subunits linked together in a multi-subunit complex.
- Once the activated protein has been formed, a payload can be attached by suitable methods, such as oxime formation when the tether contains a reactive ketone. As illustrated in
FIGS. 3A-3C and certain of the examples, a bis-aminooxy compound containing the payload can be added in one step; alternatively, an alkoxyamine having a functional group can be added to the tether, and the functional group can be used to attach the payload in a subsequent step. - The activated protein is typically contacted with an aminooxy compound containing a payload, or a group that can be used to attach a payload, without purifying or isolating the activated protein. The Examples illustrate introducing a reactive group onto the protein first, then using the reactive group to attach a cytotoxin.
- The following HPLC methods are used in the examples below.
- Eluent A: water+0.1% Formic acid, Eluent B: Acetonitrile+0.08% Formic acid
Gradient: from 3 to 80% B in 2 min−Flow 1.0 ml/min. Column: Proswift Monolith 4.6*50 mm 40° C. - Eluent A: water+0.1% Formic acid, Eluent B: Acetonitrile+0.04% Formic acid
Gradient: from 3 to 80% B in 2 min−Flow 1.0 ml/min. Column: Proswift Monolith 4.6*50 mm 40° C. - Eluent A: water+3.75 mM ammonium acetate+2% acetonitrile, Eluent B: Acetonitrile
Gradient: from 2 to 98% B in 1.7 min−Flow 1.0 ml/min. Column: Acquity CSH 2.1*50 mm 50° C. - Eluent A: water+0.05% Formic acid+3.75 mM ammonium acetate, Eluent B: Acetonitrile+0.04% Formic acid.
Gradient: from 2 to 98% B in 4.4 min−Flow 1.0 ml/min. Column: Acquity CSH 2.1*50 mm 50° C. -
- NHS-PEG4-azide (50 mg, 0.129 mmol) and triethylamine (72 μL, 0.515 mmol) were added to 1,7-bis-Boc-1,4,7-triazaheptane (47 mg, 0.155 mmol) in dichloromethane (1.3 mL). The resulting mixture was stirred at room temperature for 1 hour. Saturated aqueous sodium chloride was added, and the mixture was extracted with dichloromethane twice, and the combined extracts were dried over anhydrous magnesium sulfate. After filtration and concentration, the residue was purified by silica gel chromatography (0-40%, v/v, ethyl acetate/heptane) to the title compound 1(30 mg, 40%). LC-MS (M+1) 577.4, t=1.20 minutes. HRMS: calculated for C25H49N6O9 (MH+) 577.3561, observed 577.3548. 1H NMR (400 MHz, CDCl3) δ ppm 1.44 (br. s., 18H) 2.63 (t, J=6.28 Hz, 2H) 3.27-3.34 (m, 4H) 3.40 (t, J=5.04 Hz, 2H) 3.46-3.51 (m, 4H) 3.54-3.72 (m, 14H) 3.80 (t, J=6.33 Hz, 2H) 5.11 (br. s., 1H) 5.18 (br. s., 1H).
-
- HCl 4N in dioxane (130 μL, 0.52 mmol) was added dropwise to a solution of 1 (30 mg, 0.052 mmol) in dichloromethane (1 mL). The resulting mixture was stirred at room temperature for 30 minutes, and then concentrated in vacuo and the title compound N,N-bis(2-aminoethyl)-1-azido-3,6,9,12-tetraoxapentadecan-15-amide dihydrochloride (2, 14 mg, 60%) was obtained. LC-MS (M+1) 377.3, t=0.44 minutes
-
- 2,5-dioxopyrrolidin-1-yl 1-((1,3-dioxoisoindolin-2-yl)oxy)-3,6,9,12-tetraoxapentadecan-15-oate (35 mg, 0.069 mmol) and triethylamine (17 μL, 0.125 mmol) were added to a solution of N,N-bis(2-aminoethyl)-1-azido-3,6,9,12-tetraoxapentadecan-15-amide dihydrochloride (2, 14 mg, 0.031 mmol) in dichloromethane. The resulting mixture was stirred at room temperature for 16 hours, and then concentrated in vacuo. The title compound 1-azido-N,N-bis(1-((1,3-dioxoisoindolin-2-yl)oxy)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-yl)-3,6,9,12-tetraoxapentadecan-15-amide (3, 0.031 mmol) was obtained. LC-MS (M+1) 1163.6, t=1.12 minutes.
-
- Hydrazine monohydrate (61 μL, 1.24 mmol) was added to a solution of 1-azido-N,N-bis(1-((1,3-dioxoisoindolin-2-yl)oxy)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-yl)-3,6,9,12-tetraoxapentadecan-15-amide (3, 0.031 mmol) in dichloromethane (0.6 mL). The resulting mixture was stirred at room temperature for 1 hour, and then concentrated in vacuo. The resulting residue was purified by preparative HPLC (15-40%, v/v, acetonitrile/(5 mM aqueous NH4OH)) and the combined elutes were concentrated to yield the title compound N,N-bis(1-(aminooxy)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-yl)-1-azido-3,6,9,12-tetraoxapentadecan-15-amide (4, 13 mg, 46%). LC-MS (M+1) 903.6, t=0.65 minutes. 1H NMR (400 MHz, CDCl3) δ ppm 2.41-2.53 (m, 4H) 2.66 (t, J=6.42 Hz, 2H) 3.37-3.45 (m, 6H) 3.45-3.54 (m, 4H) 3.56-3.71 (m, 44H) 3.71-3.76 (m, 4H) 3.78 (t, J=6.37 Hz, 2H) 3.86 (br. s., 4 H).
-
- Succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate (50 mg, 0.118 mmol) and triethylamine (65 μL, 0.47 mmol) were added to a solution of 1,7-bis-Boc-1,4,7-triazaheptane (43 mg, 0.141 mmol) in dichloromethane (1.2 mL). The resulting mixture was stirred at room temperature for 1 hour. N,N-diisopropylethylamine (82 μL, 0.47 mmol) was added, and the mixture was stirred at room temperature for 16 hours. Saturated aqueous sodium chloride was added, and then the mixture was extracted twice with dichloromethane. The combined extracts were dried over anhydrous magnesium sulfate. After filtration and concentration, the residue was purified by silica gel chromatography (0-5%, v/v, methanol/dichloromethane) to give di-tert-butyl (((6-(3-(pyridin-2-yldisulfanyl)propanamido)hexanoyl)azanediyl)bis(ethane-2,1-diyl))dicarbamate
- (5, 42 mg, 58%) as colorless solid. LC-MS (M+1) 614.3, t=1.21 minutes. HRMS: calculated for C28H48N5O6S2(MH+) 614.3046, observed 614.3065. 1H NMR (400 MHz, CDCl3) δ ppm 1.31-1.74 (m, 24H) 2.37 (t, J=7.03 Hz, 2H) 2.64 (t, J=6.72 Hz, 2H) 3.11 (t, J=6.72 Hz, 2H) 3.20-3.38 (m, 6H) 3.44-3.50 (m, 4H) 5.20-5.34 (m, 2H) 6.78 (br. s., 1H) 7.19 (br. s., 1H) 7.74 (br. s., 2H) 8.50 (d, J=3.42 Hz, 1H).
-
- HCl 4N in dioxane (171 μL, 0.68 mmol) was added to a solution of di-tert-butyl (((6-(3-(pyridin-2-yldisulfanyl)propanamido)hexanoyl)azanediyl)bis(ethane-2,1-diyl))dicarbamate (5, 42 mg, 0.068 mmol) in dichloromethane (0.7 mL). The resulting mixture was stirred at room temperature for 30 minutes, and then concentrated in vacuo to yield the title compound N,N-bis(2-aminoethyl)-6-(3-(pyridin-2-yldisulfanyl)propanamido)hexanamide dihydrochloride (6, 0.068 mmol). LC-MS (M+1) 414.2, t=0.52 minutes.
-
- 2,5-dioxopyrrolidin-1-yl 1-((1,3-dioxoisoindolin-2-yl)oxy)-3,6,9,12-tetraoxapentadecan-15-oate (76 mg, 0.150 mmol) and triethylamine (38 μL, 0.272 mmol) were added to a solution of N,N-bis(2-aminoethyl)-6-(3-(pyridin-2-yldisulfanyl)propanamido)hexanamide dihydrochloride (6, 0.068 mmol) in dichloromethane (1.4 mL). The resulting mixture was stirred at room temperature for 16 hours. Saturated aqueous sodium chloride was added, and the mixture was extracted twice with dichloromethane. The combined extracts were dried over anhydrous magnesium sulfate. After filtration and concentration, the residue was purified by silica gel chromatography (0-10%, v/v, methanol/dichloromethane) to give 1-((1,3-dioxoisoindolin-2-yl)oxy)-N-(1-((1,3-dioxoisoindol in-2-yl)oxy)-15-oxo-19-(6-(3-(pyridin-2-yldisulfanyl)propanamido)hexanoyl)-3,6,9,12-tetraoxa-16,19-diazahenicosan-21-yl)-3,6,9,12-tetraoxapentadecan-15-amide (7, 47 mg, 58%) as clear oil. LC-MS (M+1) 1200.4, t=1.13 minutes. HRMS: calculated for C56H78N7O18S2(MH+) 1200.4845, observed 1200.4943. 1H NMR (400 MHz, CDCl3) δ ppm 1.31-1.74 (m, 6H) 2.40 (t, J=7.21 Hz, 2H) 2.43-2.57 (m, 4H) 2.66 (t, J=6.72 Hz, 2H) 3.12 (t, J=6.97 Hz, 2H) 3.29 (q, J=6.44 Hz, 2H) 3.35-3.55 (m, 9H) 3.55-3.67 (m, 19H) 3.67-3.80 (m, 8H) 3.88 (td, J=4.43, 2.26 Hz, 4H) 4.33-4.44 (m, 4H) 6.96 (br. s., 1H) 6.99-7.10 (m, 1H) 7.24 (br. s., 2H) 7.73-7.83 (m, 6H) 7.83-7.91 (m, 4H) 8.51 (d, J=4.77 Hz, 1H).
-
- Thiophenol (101 μL, 0.98 mmol) was added to a solution of di-tert-butyl (((6-(3-(pyridin-2-yldisulfanyl)propanamido)hexanoyl)azanediyl)bis(ethane-2,1-diyl))dicarbamate (5, 60 mg, 0.098 mmol) in dichloromethane (0.98 mL). The resulting mixture was stirred at room temperature for 30 minutes, and the mixture was concentrated in vacuo. The residue was purified by silica gel chromatography ((10-100%, v/v, ethyl acetate/heptane) to give di-tert-butyl (((6-(3-(phenyldisulfanyl)propanamido)hexanoyl)azanediyl)bis(ethane-2,1-diyl))dicarbamate (8, 35 mg, 58%) as clear oil. LC-MS (M+1) 613.2, t=1.38 minutes. HRMS: calculated for C29H49N4O6S2 (MH+) 613.3094, observed 613.3097. 1H NMR (400 MHz, CDCl3) δ ppm 1.29-1.55 (m, 22H) 1.55-1.78 (m, 2H) 2.35 (t, J=7.20 Hz, 2H) 2.56 (t, J=7.01 Hz, 2H) 3.03 (t, J=7.01 Hz, 2H) 3.16-3.36 (m, 6H) 3.37-3.53 (m, 4H) 7.14-7.30 (m, 1H) 7.30-7.41 (m, 2H) 7.47-7.59 (m, 2H).
-
- HCl 4N in dioxane (143 μL, 0.57 mmol) was added to a solution of di-tert-butyl (((6-(3-(phenyldisulfanyl)propanamido)hexanoyl)azanediyl)bis(ethane-2,1-diyl))dicarbamate (8, 35 mg, 0.057 mmol) in dichloromethane (0.6 mL). The resulting mixture was stirred at room temperature for 30 minutes, and the mixture was concentrated in vacuo to give N,N-bis(2-aminoethyl)-6-(3-(phenyldisulfanyl)propanamido)hexanamide dihydrochloride (9, 0.057 mmol). LC-MS (M+1) 413.2, t=0.67 minutes.
-
- 2,5-dioxopyrrolidin-1-yl 1-((1,3-dioxoisoindolin-2-yl)oxy)-3,6,9,12-tetraoxapentadecan-15-oate (87 mg, 0.171 mmol) and triethylamine (39 μL, 0.285 mmol) were added to a solution of N,N-bis(2-aminoethyl)-6-(3-(phenyldisulfanyl)propanamido)hexanamide dihydrochloride (9, 0.057 mmol) in dichloromethane (0.6 mL). The resulting mixture was stirred at room temperature for 1 hour. Saturated aqueous sodium chloride was added, and the mixture was extracted twice with dichloromethane. The combined extracts were dried over anhydrous magnesium sulfate. After filtration and concentration the residue was purified by silica gel chromatography (0-10%, v/v, methanol/dichloromethane) to give 1-((1,3-dioxoisoindolin-2-yl)oxy)-N-(1-((1,3-dioxoisoindolin-2-yl)oxy)-15-oxo-19-(6-(3-(phenyldisulfanyl)propanamido)hexanoyl)-3,6,9,12-tetraoxa-16,19-diazahenicosan-21-yl)-3,6,9,12-tetraoxapentadecan-15-amide (10, 45 mg, 66%) as clear oil. LC-MS (M+1) 1199.3, t=1.25 minutes. HRMS: calculated for C57H79N6O18S2 (MH+) 1199.4892, observed 1199.4955. 1H NMR (400 MHz, CDCl3) δ ppm 1.32-1.44 (m, 2H) 1.44-1.60 (m, 4H) 2.41 (t, J=7.40 Hz, 2H) 2.49 (d, J=4.89 Hz, 4H) 2.60 (br. s., 2H) 3.04 (t, J=7.09 Hz, 2H) 3.25 (d, J=4.40 Hz, 2H) 3.44 (d, J=6.85 Hz, 6H) 3.52 (br. s., 3H) 3.56-3.78 (m, 27H) 3.88 (td, J=4.31, 2.75 Hz, 4H) 4.30-4.45 (m, 4H) 7.18-7.38 (m, 3H) 7.55 (dd, J=6.91, 1.65 Hz, 2H) 7.71-7.82 (m, 4H) 7.82-7.91 (m, 4H)
-
- Hydrazine monohydrate (74 μL, 1.501 mmol) was added to a solution of 1-((1,3-dioxoisoindolin-2-yl)oxy)-N-(1-((1,3-dioxoisoindolin-2-yl)oxy)-15-oxo-19-(6-(3-(phenyldisulfanyl)propanamido)hexanoyl)-3,6,9,12-tetraoxa-16,19-diazahenicosan-21-yl)-3,6,9,12-tetraoxapentadecan-15-amide (10, 45 mg, 0.038 mmol) in dichloromethane (0.75 mL). The resulting mixture was stirred at room temperature for 30 minutes, and then concentrated in vacuo. The residue was purified by preparative HPLC (15-40%, v/v, acetonitrile/(5 mM aqueous NH4OH)). After concentration, 1-(aminooxy)-N-(1-(aminooxy)-15-oxo-19-(6-(3-(phenyldisulfanyl)propanamido)hexanoyl)-3,6,9,12-tetraoxa-16,19-diazahenicosan-21-yl)-3,6,9,12-tetraoxapentadecan-15-amide (11, 12 mg, 34%) was obtained. LC-MS ((M/2)+1) 470.6, t=1.15 minutes.
- 0.61 mL of Tris 0.1M pH 8.0, and Lys-C(100 μL of a 0.1 mg/mL solution in water) were added sequentially to IgG (0.639 mL of a 78.26 mg/mL solution in PBS pH 7.4, 0.336 μmol). The resulting mixture was incubated at 37° C. for 45 minutes. Protein A immobilized on sepharose beads were added to the mixture, and subsequently washed three times with PBS buffer to remove Lys-C and Fab fragments. Then the Fc was released by adding glycine 0.1M pH 2.5 twice, eluting into Tris 1M pH 8.0. The eluted Fc was buffer exchanged to PBS pH 7.4 using Amicon 10K MWCO centrifugal filters to give Fc (700 μL, 19.6 mg/mL, 13.7 mg, 77%). LCMS ESI (after deglycosylation with PNGase F): 50410.
-
- 900 μL of Tris 0.25M pH 7.4, and 1,3-dichloroacetone in DMSO (120 μL, 0.019 mmol) were added sequentially to a solution of Fc (10 mg, 0.189 μmol) in 510 μL PBS pH 7.4 at 4° C. The mixture was agitated at 4° C. for 10 minutes, and then TCEP.HCl in water (180 μL, 1.887 μmol) was added dropwise. The mixture was agitated at 4° C. for 20 hours. The mixture was passed through Zeba 7K MWCO (Molecular Weight Cut Off) spin columns three times to give 12 (1.8 mL, 5.35 mg/mL, 9.63 mg, 96%). LCMS ESI (after deglycosylation with PNGase F): 50521.
-
- 1,3-dichloroacetone in DMSO (9.72 μL, 1.53 μmol) was added to a solution of anti-Her2 IgG (1.5 mg, 0.010 μmol) in 82 μL of Tris (0.25M pH 7.4) at 4° C. The mixture was agitated at 4° C. for 10 minutes, and then TCEP.HCl in water (14.62 μL, 0.153 μmol) was added dropwise. The resulting mixture was agitated at 4° C. for 20 hours and then passed through Zeba 7K MWCO spin columns three consecutive times to give modified anti-Her2 IgG 13 (110 μL, 11.6 mg/mL, 1.27 mg, 85%). LCMS ESI (after deglycosylation with PNGase F): 145401.
-
- 0.4 mL of PBS pH 7.4, N,N-bis(1-(aminooxy)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-yl)-1-azido-3,6,9,12-tetraoxapentadecan-15-amide (4, 52 μL of a 30 mg/mL solution in DMSO, 1.55 mg, 1.717 μmol), and 3,5-diaminobenzoic acid in DMSO (130 μL, 0.172 mmol) were added sequentially to a solution of 12 (9.1 mg, 0.172 μmol) in 1.7 mL of PBS (pH 7.4) at room temperature. The mixture was agitated at 20° C. for 16 hours, and then concentrated by using Amicon ultra 10K MWCO centrifugal filter with PBS as the washing buffer to give the title compound 14 (310 μL, 27 mg/mL, 8.37 mg, 90%). LCMS ESI (after deglycosylation with PNGase F): 51388. See
FIG. 4 for the SDS-PAGE of the reaction product along with Fc and 12. -
- N,N-bis(1-(aminooxy)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-yl)-1-azido-3,6,9,12-tetraoxapentadecan-15-amide (4, 1.81 μL of a 30 mg/mL solution in DMSO, 54 μg, 0.060 μmol), and 3,5-diaminobenzoic acid in DMSO (2.28 μL, 3.00 μmol) were added sequentially to the modified anti-Her2 IgG (13, 441 μg, 0.003 μmol) in 38 μL of PBS (pH 7.4) at room temperature. The resulting mixture was agitated at 20° C. for 16 hours, and then passed through Zeba 7K MWCO spin columns three consecutive times to give the title compound (15, 125 μL, 3.05 mg/mL, 380 μg, 85%). LCMS ESI (after deglycosylation with PNGase F): 147132. See
FIG. 5 for SDS-PAGE of this product along with the antibody alone (TBS) and another TBS conjugate not included here. -
- 1-(aminooxy)-N-(1-(aminooxy)-15-oxo-19-(6-(3-(phenyldisulfanyl)propanamido)hexanoyl)-3,6,9,12-tetraoxa-16,19-diazahenicosan-21-yl)-3,6,9,12-tetraoxapentadecan-15-amide (11, 8.44 μL of a 30 mg/mL solution in DMSO, 253 μg, 0.269 μmol), and 3,5-diaminobenzoic acid in DMSO (5.12 μL, 6.74 μmol) were added to the modified anti-Her2 IgG (13, 2 mg, 0.013 μmol) in 135 μL of PBS (pH 7.4) at room temperature. The mixture was agitated at 20° C. for 16 hours, and then passed through Zeba 7K MWCO spin columns three consecutive times to give the title compound 16 (150 μL, 9.24 mg/mL, 1.4 mg, 69%). LCMS ESI (after deglycosylation with PNGase F): 147204.
-
- A solution of TCEP.HCl in water (0.88 μL, 0.092 μmol) was added dropwise to anti-Her2 IgG with—phenyldisulfides 16 (0.69 mg, 0.0046 μmol) in 75 μL of PBS (pH 7.4) at room temperature. The resulting mixture was agitated at 20° C. for 20 minutes, and then passed through Zeba 7K MWCO spin columns (pre-equilibrated with PBS 0.1M+EDTA 10 mM, pH 7.4) three consecutive times. (S)-2-((2R,3S)-3-((R)-1-((3R,4S,5S)-4-((R)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-methylhexanamido)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl) pyrrolidin-3-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoic acid (4.27 μL, 0.092 μmol, 20 mg/mL in DMSO) was then added, and the mixture was agitated at 20° C. for 16 hours. The mixture was passed through Zeba 7K MWCO spin columns three consecutive times to give the title compound 17 (100 μL, 4.93 mg/mL, 493 μg, 70%). LCMS ESI (after deglycosylation with PNGase F): 146987 (10% by peak intensity, anti-Her2 IgG-linker, +0 MMAF), 148839 (90% by peak intensity, anti-Her2 IgG-diMMAF, +2 MMAF). The average DAR for the final product was estimated as 1.8 based on ESI-MS peaks. See
FIG. 6 for the SDS-PAGE of this product along with the precursor and anti-Her2 IgG. - Into PBS solution of proteins (5 μg, 0.00017 μmol) was added TCEP HCl solution (1 μl, 0.5 M, 0.5 μmol). The resulting mixture was incubated at 37° C. for 30 min.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/524,951 US20190381126A1 (en) | 2014-05-23 | 2019-07-29 | Methods for making conjugates from disulfide-containing proteins |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462002585P | 2014-05-23 | 2014-05-23 | |
PCT/US2015/032126 WO2015179734A1 (en) | 2014-05-23 | 2015-05-22 | Methods for making conjugates from disulfide-containing proteins |
US201615312267A | 2016-11-18 | 2016-11-18 | |
US16/524,951 US20190381126A1 (en) | 2014-05-23 | 2019-07-29 | Methods for making conjugates from disulfide-containing proteins |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/312,267 Division US10406198B2 (en) | 2014-05-23 | 2015-05-22 | Methods for making conjugates from disulfide-containing proteins |
PCT/US2015/032126 Division WO2015179734A1 (en) | 2014-05-23 | 2015-05-22 | Methods for making conjugates from disulfide-containing proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190381126A1 true US20190381126A1 (en) | 2019-12-19 |
Family
ID=53366291
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/312,267 Active 2036-04-24 US10406198B2 (en) | 2014-05-23 | 2015-05-22 | Methods for making conjugates from disulfide-containing proteins |
US16/524,951 Abandoned US20190381126A1 (en) | 2014-05-23 | 2019-07-29 | Methods for making conjugates from disulfide-containing proteins |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/312,267 Active 2036-04-24 US10406198B2 (en) | 2014-05-23 | 2015-05-22 | Methods for making conjugates from disulfide-containing proteins |
Country Status (6)
Country | Link |
---|---|
US (2) | US10406198B2 (en) |
EP (1) | EP3145552B1 (en) |
JP (1) | JP6721572B2 (en) |
CN (1) | CN106536560B (en) |
ES (1) | ES2792598T3 (en) |
WO (1) | WO2015179734A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11110178B2 (en) | 2016-07-07 | 2021-09-07 | The Board Of Trustees Of The Leland Standford Junior University | Antibody adjuvant conjugates |
US11400164B2 (en) | 2019-03-15 | 2022-08-02 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
WO2018187856A1 (en) * | 2017-04-12 | 2018-10-18 | Kardium Inc. | Medical device systems and methods including helically configured or twisted, non-helically configured elongate members |
FR3131835A1 (en) * | 2022-01-17 | 2023-07-21 | Mc Saf | Method for preparing antibody-drug conjugates |
FR3131836A1 (en) * | 2022-01-17 | 2023-07-21 | Mc Saf | Antibody-drug conjugates for therapeutic use |
CN117147824A (en) * | 2022-05-29 | 2023-12-01 | 菲鹏生物股份有限公司 | Antibody conjugate and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996041813A2 (en) * | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
US8673848B2 (en) * | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
WO2008157380A2 (en) | 2007-06-15 | 2008-12-24 | Adherex Technologies Inc. | Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor |
EP2889624B1 (en) | 2009-08-10 | 2018-10-03 | UCL Business PLC | Reversible covalent linkage of functional molecules |
EP2822597A1 (en) * | 2012-03-09 | 2015-01-14 | UCL Business Plc. | Chemical modification of antibodies |
AU2013279099A1 (en) * | 2012-06-19 | 2014-12-18 | Polytherics Limited | Novel process for preparation of antibody conjugates and novel antibody conjugates |
EP2911700B1 (en) * | 2012-10-24 | 2017-02-08 | Polytherics Limited | Drug-protein conjugates |
NO2789793T3 (en) * | 2012-10-24 | 2018-01-27 | ||
CA2888445A1 (en) | 2012-11-30 | 2014-06-05 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
-
2015
- 2015-05-22 ES ES15727792T patent/ES2792598T3/en active Active
- 2015-05-22 WO PCT/US2015/032126 patent/WO2015179734A1/en active Application Filing
- 2015-05-22 CN CN201580039878.9A patent/CN106536560B/en active Active
- 2015-05-22 US US15/312,267 patent/US10406198B2/en active Active
- 2015-05-22 JP JP2017513617A patent/JP6721572B2/en active Active
- 2015-05-22 EP EP15727792.2A patent/EP3145552B1/en active Active
-
2019
- 2019-07-29 US US16/524,951 patent/US20190381126A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11110178B2 (en) | 2016-07-07 | 2021-09-07 | The Board Of Trustees Of The Leland Standford Junior University | Antibody adjuvant conjugates |
US11547761B1 (en) | 2016-07-07 | 2023-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
US11400164B2 (en) | 2019-03-15 | 2022-08-02 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
Also Published As
Publication number | Publication date |
---|---|
JP2017525750A (en) | 2017-09-07 |
ES2792598T3 (en) | 2020-11-11 |
EP3145552B1 (en) | 2020-03-04 |
CN106536560B (en) | 2021-03-09 |
CN106536560A (en) | 2017-03-22 |
EP3145552A1 (en) | 2017-03-29 |
WO2015179734A1 (en) | 2015-11-26 |
JP6721572B2 (en) | 2020-07-15 |
US20170095572A1 (en) | 2017-04-06 |
US10406198B2 (en) | 2019-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190381126A1 (en) | Methods for making conjugates from disulfide-containing proteins | |
US11311400B2 (en) | Methods for making conjugates from disulfide-containing proteins | |
US10172948B2 (en) | Methods for oxime conjugation to ketone-modified polypeptides | |
US20200345863A1 (en) | Ligand-drug-conjugate comprising a single molecular weight polysarcosine | |
JP2018510864A (en) | Antibody capable of binding by transglutaminase and conjugate produced thereby | |
US20230338562A1 (en) | Methods for the preparation of linker payload constructs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HU, QI-YING;ALLAN, MARTIN;SIGNING DATES FROM 20140827 TO 20140829;REEL/FRAME:050466/0986 |
|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.;REEL/FRAME:050870/0015 Effective date: 20140829 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |